Cosmo Pharmaceuticals N.V./Fr. COPN
07:00
09:05
11:10
13:15
15:20
1D1W1MYTD1Y5YMAX
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company based in Lainate, Italy, focusing on the development and manufacturing of products for specific gastrointestinal diseases. The company's core business involves oral therapies, particularly for conditions such as inflammatory bowel disease and colon cancer. Notable products include Lialda/Mezavant, a treatment for ulcerative colitis, and Eleview, a medical device used in endoscopic procedures. Cosmo Pharmaceuticals leverages proprietary drug delivery technologies to enhance treatment efficacy and patient compliance. While headquartered in Italy, it operates primarily within the European market and maintains a strategic partnership network to expand its global reach.
Ticker
Fr. COPN
Sector
Primary listing
XSWX
Employees
325
Headquarters
Dublin, Ireland
COPN Metrics
BasicAdvanced
CHF 1.3bn
-
-CHF 0.21
1.55
CHF 3.84
2.43%
Price and volume
Market cap
CHF 1.3bn
Beta
1.55
52-week high
CHF 129.40
52-week low
CHF 53.40
Average daily volume
53k
Dividend rate
CHF 3.84
Financial strength
Current ratio
7.181
Quick ratio
5.801
Long term debt to equity
0.727
Total debt to equity
0.872
Interest coverage (TTM)
-57.80%
Profitability
EBITDA (TTM)
4.626
Gross margin (TTM)
48.53%
Net profit margin (TTM)
-3.46%
Operating margin (TTM)
-6.66%
Effective tax rate (TTM)
-280.17%
Revenue per employee (TTM)
CHF 292,470
Management effectiveness
Return on assets (TTM)
-0.69%
Return on equity (TTM)
-0.70%
Valuation
Price to revenue (TTM)
13.284
Price to book
2.67
Price to tangible book (TTM)
4.25
Price to free cash flow (TTM)
-77.112
Free cash flow yield (TTM)
-1.30%
Free cash flow per share (TTM)
-1.027
Dividend yield (TTM)
4.85%
Forward dividend yield
2.43%
Growth
Revenue change (TTM)
-60.95%
Earnings per share change (TTM)
-102.78%
3-year revenue growth (CAGR)
0.68%
10-year revenue growth (CAGR)
5.56%
3-year earnings per share growth (CAGR)
-40.05%
10-year earnings per share growth (CAGR)
-35.10%
3-year dividend per share growth (CAGR)
25.99%
10-year dividend per share growth (CAGR)
4.14%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs